Herpes virus might drive Alzheimer's pathology
Science Daily: Pharmacology News
JANUARY 2, 2025
Viral infections may play a role in Alzheimer's disease.
Disease Science Virus 
System to auto-detect new variants will inform better response to future infectious disease outbreaks
Science Daily: Pharmacology News
JANUARY 1, 2025
Researchers have come up with a new way to identify more infectious variants of viruses or bacteria that start spreading in humans -- including those causing flu, COVID, whooping cough and tuberculosis.
Virus 
359
359 Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zika uses human skin as 'mosquito magnet' to spread virus further
Science Daily: Pharmacology News
JANUARY 30, 2025
Zika virus hijacks the skin of its human host to send out chemical signals that lure more mosquitoes to infect and spread the disease further, new research shows.
Virus 194
194 
Researchers have cracked the cellular code on protein folding, offering hope for new therapeutic avenues for many diseases
Science Daily: Pharmacology News
DECEMBER 4, 2023
While we often think of diseases as caused by foreign bodies -- bacteria or viruses -- there are hundreds of diseases affecting humans that result from errors in cellular production of its proteins.
Disease 234
234 
Genetic tracing at the Huanan Seafood market further supports COVID animal origins
Science Daily: Pharmacology News
SEPTEMBER 19, 2024
A new study provides a list of the wildlife species present at the market from which SARS-CoV-2, the virus responsible for the COVID-19 pandemic, most likely arose in late 2019. The study is based on a new analysis of metatranscriptomic data released by the Chinese Center for Disease Control and Prevention (CDC).
Marketing 338
338 
Treatments for poxviruses -- including those causing mpox and smallpox -- may already exist in licensed drugs
Science Daily: Pharmacology News
AUGUST 9, 2023
The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.
Licensing 165
165 
Chewing Gum Reveals Stone Age Diet and Disease
PLOS: DNA Science
JANUARY 25, 2024
DNA Science has described intriguing sources of environmental DNA, aka eDNA: DNA in Strange Places: Hippo Poop, Zoo Air, and Cave Dirt and A Glimpse of the Ocean’s Twilight Zone Through Environmental DNA. The post Chewing Gum Reveals Stone Age Diet and Disease appeared first on DNA Science.
Disease 97
97 
Researchers engineer in vivo delivery system for prime editing, partially restoring vision in mice
Broad Institute
JANUARY 8, 2024
Williams January 8, 2024 Credit: Susanna Hamilton, Broad Communications Researchers have developed virus-like particles that can deliver gene-editing cargo to cells, including those in the mouse brain. Delivery dilemma Gene editing approaches promise to treat a range of diseases by precisely correcting genetic mutations that cause disease.
Engineering 144
144 
New gene delivery vehicle shows promise for human brain gene therapy
Broad Institute
MAY 16, 2024
The enormous challenge of getting therapies past this barrier — a highly selective membrane separating the blood from the brain — has stymied the development of safer and more effective gene therapies for brain diseases for decades.
Therapies 137
137 
Novel formulation boosts antimicrobial properties of the natural hand barrier
SCIENMAG: Medicine & Health
SEPTEMBER 7, 2023
Hand washing and disinfection are important hygiene practices to minimize the probability of catching infectious diseases. While this had been known to science […] Contact infection is among the most common ways pathogens, such as bacteria and viruses, spread from one person to another.
Virus 84
84 
Gilead Sciences Completes Acquisition of MYR GmbH
The Pharma Data
MARCH 5, 2021
Gilead Sciences, Inc. The acquisition provides Gilead with Hepcludex ® (bulevirtide), which was conditionally approved by the European Medicines Agency for the treatment of chronic hepatitis delta virus (HDV) in adults with compensated liver disease in July 2020. About Gilead Sciences. Gilead Sciences, Inc.
Science 52
52 
Investigational COVID mucosal vaccine protects against disease and transmission
The Pharma Data
MAY 5, 2022
In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spread of the virus to other close contacts. The findings are published today in the journal Science Translational Medicine. Science Translational Medicine, 2022.
Vaccine 52
52 
Designing a Better Probiotic. CRISPR Hubris?
PLOS: DNA Science
FEBRUARY 8, 2024
Already, engineered probiotics have been used to treat metabolic disorders like inflammatory bowel disease and obesity, single-gene conditions like PKU, and bacterial infections common in people who have cystic fibrosis. Or, add genes to arm a host species to resist a specific infectious disease. Probiotics are an enticing target.
Scientists map the locations of hundreds to thousands of cell types across a mammalian brain
Broad Institute
DECEMBER 13, 2023
Related news Researchers map brain cell changes in Alzheimer’s disease Courtesy of the Chen and Macosko labs. The researchers also discovered clues about cellular function and the potential roles of brain structures in disease. Courtesy of the Chen and Macosko labs. Our results underscore the need to study them more deeply.”
DNA 140
140 
Top 10 Life Science Resources for Summer 2024
Alta Sciences
JULY 25, 2024
Top 10 Life Science Resources for Summer 2024 pmjackson Thu, 07/25/2024 - 14:44 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for your convenience. Tags Science and Health Weight 16 the UK, or the EU.
Science 52
52 
Accelerating Vaccine Development for the Novel Infectious Disease with Pseudoviruses
PerkinElmer
MAY 28, 2020
Time is of the essence when it comes to the development of a vaccine for the novel infectious disease in our current pandemic. Unfortunately, the road towards treatment can be time-consuming, especially when utilizing assays with live virus.
Vaccine 52
52 
#WhyIScience Q&A: A process development lead returns to her research roots
Broad Institute
MAY 30, 2023
By Andrea Tamayo May 30, 2023 Credit: Allison Dougherty, Broad Communications Isabella Teixeira-Soldano studies single cells to better understand disease progression. Isabella Teixeira-Soldano began her career in science sifting through mud. What inspires you to keep working in your field?
Research 89
89 
Women in Stem with Dr Emily Leproust
Drug Target Review
SEPTEMBER 28, 2023
They had the science and the technology but not the business model. They needed reference materials for the disease in order to develop and validate diagnostic tests. For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus.
DNA 116
116 
Evolved prime editors are smaller and more efficient for therapeutic applications
Broad Institute
AUGUST 31, 2023
Related News Next generation prime editing systems move closer to possible therapeutic applications New CRISPR genome editing system offers a wide range of versatility in human cells Prime editing technologies allow scientists to precisely edit the genome in a variety of ways and could one day be used to treat genetic diseases.
DNA 145
145 
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
The Pharma Data
JANUARY 31, 2021
–( BUSINESS WIRE )– Gilead Sciences, Inc. While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. 1, 2021 11:00 UTC. FOSTER CITY, Calif. &
Vaccine 52
52 
HIGH SCHOOL SCIENTISTS AND ENGINEERS WIN NEARLY $9 MILLION AT THE REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR 2023
The Pharma Data
MAY 19, 2023
HIGH SCHOOL SCIENTISTS AND ENGINEERS WIN NEARLY $9 MILLION AT THE REGENERON INTERNATIONAL SCIENCE AND ENGINEERING FAIR 2023 Regeneron Pharmaceuticals, Inc. Other top prizes went to projects in the fields of computational biology, animal sciences and neurobiology.
Engineering 52
52 
Novartis, Voyager Therapeutics reach license option agreement for next-generation gene therapy vectors for neurological diseases
The Pharma Data
MARCH 9, 2022
Novartis today announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three capsids to use in potential gene therapies for neurological diseases, with options to access capsids for two other targets. About Novartis.
Licensing 52
52 
Advances in the Battle Against Autoimmune Disease
The Pharma Data
DECEMBER 15, 2020
A healthy immune system defends the body against disease and other conditions. Autoimmune disease impacts different parts of the body, weakening functionality. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. It may be life-threatening.
Disease 52
52 
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
The Pharma Data
APRIL 26, 2022
NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. The medical need for vaccination against Lyme disease is steadily increasing as the geographic footprint of the disease widens7.
Vaccine 52
52 
Topical Gene Therapy FDA-Approved for Severe Skin Disease, Dystrophic Epidermolysis Bullosa
PLOS: DNA Science
JUNE 1, 2023
This DNA Science post from 2018 traces the history of the efforts. Peter Marinkovich, MD, director of the Blistering Disease Clinic at Stanford Health Care, calls DEB a devastating disease. A dominant form – DDEB – is less severe, blistering the hands, feet, knees, and elbows. Primary investigator M.
FDA Approval 52
52 
Oyagen, Inc. Publishes Study On Its OYA1 As A “Highly Effective” Experimental Drug Candidate For Treating Infections By The Ebola Virus
The Pharma Data
JANUARY 6, 2021
A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures.’ The published study results showed that OYA1 was “highly effective” in reducing the spread of Ebola Virus infection in laboratory tests with the live Ebola virus carried out by NIAID.
Virus 40
40 
Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
The Pharma Data
MARCH 8, 2021
The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. About Molnupiravir.
Trials 69
69 
The effectiveness of nanoparticles in chemotherapy
Drug Target Review
NOVEMBER 24, 2023
The use of nanoparticles, which are around the size of a virus particle, is a very promising delivery method for overcoming chemotherapy issues. 1 Dr Ninh (Irene) La-Beck, from the Department of Immunotherapeutics and Biotechnology at the Texas Tech University Health Sciences Center (TTUHSC) Jerry H.
Immune Response 111
111 
Farma: Speculative Gastronomy
Codon
OCTOBER 13, 2024
” From their first intrepid steps into the fields, GM crops have become a scapegoat for distrust in science and its overextension into formerly “unadulterated” products. One of these is “citrus canker,” a bacterial disease that causes the fruits to develop necrotic lesions. Yields were devastated.
Engineering 101
101 
Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial
SCIENMAG: Medicine & Health
OCTOBER 18, 2023
This study is conducted by the Jiangsu Provincial Center for Disease Control and Prevention, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Vaccines for Infectious Diseases of Xiamen University, China National Institutes for Food and Drug Control, and Xiamen Innovax Biotech Company.
Vaccine 52
52 
Janssen Announces Novel Mechanism of Action that Shows Promise Against Dengue in Data Published in Nature
The Pharma Data
OCTOBER 6, 2021
1] This research builds on Johnson & Johnson’s work to advance science against emerging and entrenched global public health threats. We are hopeful that this early-stage science can ultimately translate into a meaningful difference for at risk communities. Janssen is now moving its dengue program into clinical development.
Virus 52
52 
Charelisse Guevara Reyes
Broad Institute
SEPTEMBER 26, 2024
Their dedication, enthusiasm for science, love, and support made this experience unique. Lastly, BSRP is about science, leadership, community, and, most importantly, change. I cannot wait to see all the changes we will make in the world and how we will use all the lessons to transform the science community.
Science 52
52 
AI Model Predicts Drug Synergies for Fighting COVID-19
Nvidia Developer: Drug Discovery
OCTOBER 5, 2021
Recently published in the Proceedings of the National Academy of Sciences , the research develops a deep learning model that determines the best drug combinations for fighting the virus, despite having relatively limited data. Read the full article in the Proceedings of the National Academy of Sciences >> Read more >>
Drugs 52
52 
Protein Mapping Study Reveals Valuable Clues for COVID-19 Drug Development
NIH Director's Blog: Drug Development
OCTOBER 27, 2020
Science, 2020 One way to fight COVID-19 is with drugs that directly target SARS-CoV-2, the novel coronavirus that causes the disease. Another promising strategy is drugs that target the proteins within human cells that the virus needs to infect, multiply, and spread. Credit: DE Gordon et al., Gordon DE et al.
Protein offers promise for treatment of reproductive conditions
Drug Target Review
OCTOBER 25, 2023
Dr Tal, Assistant Professor of Obstetrics, Gynaecology and Reproductive Sciences at Yale School of Medicine and senior author of the study, said: “Previous findings imply there is an important function for CXCR4 in pregnancy.” Many of these adaptations happen within the decidua, tissue that surrounds and interacts with the placenta.
Treatment 106
106 
Q&A: How Terra became a backbone of public health pathogen surveillance
Broad Institute
SEPTEMBER 30, 2024
Today, about a third of Broad’s Terra users are from the public health workforce; in the US, 76 state and local public health labs use the platform for preventing and monitoring infectious disease spread in their communities. This was true in the US and all the more in the Global South, where the burden of infectious disease is the highest.
Bioinformatics 101
101 
The Effectiveness of DIY Air Filtration Units
NIOSH Science Blog: Drugs
FEBRUARY 3, 2023
Air filtration units were widely used during large wildfire outbreaks in the western United States,[1] and their use surged nationwide during the COVID-19 pandemic as a way to reduce exposure to aerosols containing the SARS-CoV-2 virus.
Virus 97
97 
Thinking impaired in 60% of COVID-19 survivors
The Pharma Data
AUGUST 1, 2021
In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San Antonio reported July 29 at the Alzheimer’s Association International Conference. That is worrisome,” Dr. de Erausquin said.
Virus 52
52 
Bringing Needed Structure to COVID-19 Drug Development
NIH Director's Blog: Drug Development
APRIL 2, 2020
Science, 2020. With so much information swirling around these days about the coronavirus disease 2019 (COVID-19) pandemic, it would be easy to miss one of the most interesting and significant basic science reports of the past few weeks. ACE2 is the receptor that the virus uses to gain entry. Credit: Adapted from Yan R.,
Regeneron’s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention
The Pharma Data
OCTOBER 28, 2020
In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.
Virus 40
40 
Gilead applies for FDA approval to treat coronavirus patients with remdesivir
The Pharma Data
AUGUST 11, 2020
Gilead Sciences has asked the FDA to approve its drug remdesivir to treat COVID-19 patients. It has not received general approval to treat the virus in the US, but has in several European countries and Japan. It has not received general approval to treat the virus in the US, but has in several European countries and Japan.
FDA Approval 52
52 
Assembly Biosciences Appoints Gina Consylman to Board of Directors
The Pharma Data
OCTOBER 19, 2020
Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors. SOUTH SAN FRANCISCO, Calif., 20, 2020 (GLOBE NEWSWIRE) — Assembly Biosciences , Inc.
Virus 52
52 
Medicago and GSK announce the approval by Health Canada of COVIFENZ®, an adjuvanted plant-based COVID-19 vaccine
The Pharma Data
FEBRUARY 24, 2022
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent coronavirus disease 2019 (COVID?19)
Vaccine 52
52 
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
The Pharma Data
JANUARY 31, 2021
Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. . CHENGDU, China , Feb.
Let's personalize your content